Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 2
1999 2
2001 3
2002 2
2003 4
2004 4
2005 3
2006 6
2007 5
2008 1
2009 2
2010 1
2011 2
2012 1
2013 1
2014 1
2015 5
2016 5
2017 7
2018 11
2019 14
2020 13
2021 14
2022 12
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 34281881

111 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.
Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y. Morisaki T, et al. Anticancer Res. 2021 Aug;41(8):4101-4115. doi: 10.21873/anticanres.15213. Anticancer Res. 2021. PMID: 34281881
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T, Hikichi T, Onishi H, Morisaki T, Kubo M, Hirano T, Yoshimura S, Kiyotani K, Nakamura Y. Morisaki T, et al. Immunol Invest. 2021 Jul;50(5):562-579. doi: 10.1080/08820139.2020.1778721. Epub 2020 Jul 13. Immunol Invest. 2021. PMID: 32660279
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Yew PY, Yoshimura S, Onishi H, Nakamura M, Nakamura Y, Morisaki T. Ichimiya S, et al. Immunol Invest. 2022 Jul;51(5):1498-1514. doi: 10.1080/08820139.2021.1973491. Epub 2021 Sep 5. Immunol Invest. 2022. PMID: 34486463
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG. Lesterhuis WJ, et al. Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19. Clin Cancer Res. 2011. PMID: 21771874 Free article.
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. Sarivalasis A, et al. J Transl Med. 2019 Nov 26;17(1):391. doi: 10.1186/s12967-019-02133-w. J Transl Med. 2019. PMID: 31771601 Free PMC article.
Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, Li G, Xiong W, Zeng Z. Peng M, et al. Mol Cancer. 2019 Aug 23;18(1):128. doi: 10.1186/s12943-019-1055-6. Mol Cancer. 2019. PMID: 31443694 Free PMC article. Review.
111 results